Get the Stockscreener App
13.65
2.64%
-0.37
Keros Therapeutics Inc stock is traded at $13.65, with a volume of 546.34K.
It is down -2.64% in the last 24 hours and up +32.14% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$14.02
Open:
$13.89
24h Volume:
546.34K
Relative Volume:
0.53
Market Cap:
$594.96M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-2.6608
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
-6.83%
1M Performance:
+32.14%
6M Performance:
-79.90%
1Y Performance:
-76.30%
1-Day Range:
$13.57
$14.22
1-Week Range:
$13.43
$14.80
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
13.65 | 594.96M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by DAFNA Capital Management LLC - MarketBeat
HC Wainwright Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00 - MarketBeat
What is Leerink Partnrs' Estimate for KROS FY2025 Earnings? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified - simplywall.st
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - MarketBeat
Barclays PLC Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
JPMorgan Chase & Co. Acquires Significant Stake in Keros Therapeutics Inc. - GuruFocus
Alkeon Capital Management LLC Trims Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Reinforces Commitment to Maximizing Stockholder Value - GlobeNewswire
Keros Reinforces Commitment to Maximizing Stockholder Value | KROS Stock News - Stock Titan
ADAR1 Capital Management urges Keros Therapeutics for board change - Seeking Alpha
Keros Therapeutics Stockholder ADAR1 Seeks Business Restructuring Alleging Prolonged Underperformance - marketscreener.com
ADAR1 Capital Management Calls For Keros Therapeutics To Restructure Business, Reduce Headcount - marketscreener.com
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders | KROS Stock News - Stock Titan
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - marketscreener.com
Keros Therapeutics stock target cut to $25 at H.C. Wainwright By Investing.com - Investing.com India
Keros Therapeutics stock target cut to $25 at H.C. Wainwright - Investing.com
KROS Stock Target Cut by Analyst Amid Trial Setback | KROS Stock News - GuruFocus
Braidwell LP Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Wells Fargo & Company MN Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
MetLife Investment Management LLC Purchases 1,027 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics Reports Strong Q1 2025 Results - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Tower Research Capital LLC TRC - MarketBeat
Boxer Capital Management LLC Invests $3.96 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Keros Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
KROS Reports Strong Q1 Earnings Boosted by License Agreement | KROS Stock News - GuruFocus
Keros Therapeutics Swings to Massive $148M Profit as Phase 1 Trial Hits Key Goals - Stock Titan
(KROS) Long Term Investment Analysis - news.stocktradersdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat
TCG Crossover Management LLC Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Darwin Global Management Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Nebula Research & Development LLC Has $1.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
544,001 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Lynx1 Capital Management LP - MarketBeat
Keros Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Was Keros Therapeutics Inc (KROS)’s session last reading good? - uspostnews.com
Implied Volatility Surging for Keros Therapeutics Stock Options - Yahoo Finance
Keros Therapeutics Inc [KROS] 10% Owner makes an insider purchase of 934,258 shares worth 9.46 million. - knoxdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Russell Investments Group Ltd. - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $40.33 - Defense World
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):